The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance VAV1 MGDs
Oct 28, 2024•over 1 year ago
Contract Type
agreement
PhiladelphiaBiotechnology
Description
Monte Rosa Therapeutics, Inc. has announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 Molecular Glue Degraders. The agreement is expected to accelerate the clinical development of MRT-6160 and explore therapeutic opportunities across various indications. Additionally, Monte Rosa will receive an up-front payment of $150 million and is eligible for milestone payments, U.S
Company Information
Company
ViTToria Biotherapeutics, Inc.
Location
3675 MARKET STREET
Philadelphia, Pennsylvania, United States
About
Pioneering Therapies for Cancer and Beyond – Our drug discovery platform is tailored to promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, undruggable proteins, in essence leading to pharmacological protein knockout with high efficiency and accuracy.
Predictive Intelligence
Strategic
ML-powered predictions for ViTToria Biotherapeutics, Inc.'s next move
PhiladelphiaBiotechnology